These results indicate that cisplatin-treated Oasl1−/− mice have more tumor-attacking CD8+ T cells and NK cells that can effectively kill growing tumors in the lungs, leading to improved survival of cisplatin-treated Oasl1−/− mice. This evidence concerns the gene CD8A and neoplasm.